ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

MLTX MoonLake Immunotherapeutics

45.26
2.69 (6.32%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
MoonLake Immunotherapeutics MLTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
2.69 6.32% 45.26 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
43.51 43.405 45.465 45.26 42.57
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
10/4/202406:00BWMoonLake Immunotherapeutics Inks Three-Year Technology..
11/3/202407:01EDGAR2Form 8-K - Current report
10/3/202411:00GLOBEMoonLake announces significant improvements with Nanobody®..
04/3/202407:00GLOBEMoonLake Immunotherapeutics to present MIRA trial data of..
29/2/202418:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202418:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202407:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202407:03EDGAR2Form 8-K - Current report
29/2/202407:00GLOBEMoonLake Immunotherapeutics Reports Full Year 2023 Financial..
26/2/202408:00EDGAR2Form 8-K - Current report
26/2/202407:00GLOBEMoonLake Immunotherapeutics Announces Positive Feedback from..
23/2/202415:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202417:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202417:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202417:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:02EDGAR2Form 144 - Report of proposed sale of securities
15/2/202407:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:05EDGAR2Form 144 - Report of proposed sale of securities
21/12/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202315:16EDGAR2Form 144 - Report of proposed sale of securities
19/12/202315:34EDGAR2Form 144 - Report of proposed sale of securities
14/11/202307:00GLOBEMoonLake Immunotherapeutics Reports Third Quarter 2023..
06/11/202306:55EDGAR2Form 8-K - Current report
05/11/202310:00GLOBEMoonLake Immunotherapeutics announces landmark Phase 2..
16/10/202305:16EDGAR2Form 8-K - Current report
15/10/202308:03GLOBEMoonLake Immunotherapeutics announces the full dataset from..
11/10/202309:15GLOBEMoonLake Immunotherapeutics presents positive 12-week data..
04/10/202306:01GLOBEPhase 2 MIRA primary analysis trial results (12-week) for..
06/9/202306:00GLOBEMoonLake Immunotherapeutics to host a Capital Markets Day on..
10/8/202306:00GLOBEMoonLake Immunotherapeutics Reports Second Quarter 2023..
25/7/202307:00GLOBEMoonLake completes patient randomization ahead of schedule..
17/7/202306:30IHMARKETNEWSMonday’s Wall Street Highlights: Microsoft, Santander,..
28/6/202304:00GLOBEMoonLake Immunotherapeutics Announces Pricing of $400..
26/6/202315:01GLOBEMoonLake Immunotherapeutics Announces Proposed Underwritten..
25/6/202308:00GLOBEMoonLake Immunotherapeutics achieves landmark milestone with..
12/5/202306:45GLOBEMoonLake Immunotherapeutics Reports First Quarter 2023..

Su Consulta Reciente

Delayed Upgrade Clock